Lamberto has a long and highly successful career as a senior executive in the pharmaceutical industry. Earlier this year, Lamberto retired as Chairman of Bristol Myers Squibb (BMS), one of the largest and most successful global pharmaceutical companies, with annual revenues of approximately $20 billion and market capitalization of approximately $100 billion.
Lamberto first joined BMS in 1998 as Vice President and General Manager of European oncology and Italy, and advanced to President, Europe in 2000, President, International in 2002 and President, Pharmaceuticals in 2005. He became Chief Operating Officer in 2008 and was elected to the Board of Directors the following year. He was appointed CEO in 2010, and ultimately appointed Chairman of the Board in 2015.
During Lamberto’s tenure at BMS, he was credited with leading the company in enhancing the value of the company’s pipeline, generating blockbuster sales, negotiating valuable partnerships with other major pharmaceutical companies and achieving excellent shareholder returns. Among many other accomplishments under Lamberto’s leadership, BMS led the development of a new class of drugs in immuno-oncology, which has revolutionized the treatment of many cancers.
Before joining BMS, Lamberto held the positions of Senior Corporate Vice President and President of Oncology at Pharmacia & Upjohn, and served in various senior roles at Recordati, Farmitalia Carlo Erba and KABI Pharmacia previously.
Lamberto also is a member of the Board of Directors of DowDuPont following the merger of DuPont and The Dow Chemical Company. He also serves as a Director for the American Italian Cancer Foundation.
Originally from Rome, Italy, Lamberto received his Bachelor’s degree in Engineering from Università La Sapienza of Rome and his Master of Science degree from the Massachusetts Institute of Technology.
Lamberto is well known to Dr. Göran Ando, our London office-based Senior Advisor, from their days of working together at Pharmacia.